This invention concerns in general treatment of diseases and pathological
conditions with anti-VEGF antibodies. More specifically, the invention
concerns the treatment of human patients susceptible to or diagnosed with
cancer using an anti-VEGF antibody, preferably in combination with one or
more additional anti-tumor therapeutic agents.